REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc., trading under the ticker TZAC, is a blank check company formed to pursue a business combination in the pharmaceutical and biotechnology sector. The company filed a Form 10-Q with the Securities and Exchange Commission on July 3, 2019, under accession number 0001144204-19-033793, reflecting its reporting obligations as a publicly traded special purpose acquisition company. TZAC conducted its IPO in 2019, targeting life sciences and healthcare targets consistent with its disclosed acquisition criteria. The SPAC operated within a sector that saw continued investor interest during that period given the pipeline-driven nature of pharmaceutical deal flow. Investors and researchers seeking full filing history, trust details, and sponsor data for TZAC can access the complete SpacDesk profile by signing up at SpacDesk.com.